Project description:To ascertain which genes are involved in the outcome of Leishmania infantum infection and immunopathology of human visceral leishmaniasis (VL), we investigated the transcriptional profile of whole blood samples from patients diagnosed with active VL compared to asymptomatic individuals (positive serology for Leishmania, but without clinical signs of disease) and healthy control samples.

2020-08-06 | E-MTAB-8818 | biostudies-arrayexpress

Project description:tNGS

| PRJNA1047270 | ENA

Single cell analysis of newly diagnosed AML patients

Project description:Acute Myeloid Leukemia (AML) is a heterogenous disease characterized by immature blasts at different maturation stage. We used single cell sequencing technique to analyze newly diagnosed AML patients.

2023-12-18 | GSE239721 | GEO

Single cell analysis of newly diagnosed AML patients

Project description:Single cell analysis of newly diagnosed AML patients

| PRJNA1000621 | ENA

Expression of vesicular miRNAs from plasma of Brazilian breast cancer patients diagnosed before 40 years old

Project description:in this study, we aimed to determine the vesicular miRNA profile between four cohorts of BC patients according to main molecular subtypes. These samples were classified according to their age at diagnosis in two groups: Young (diagnosed before 40 years old) and Elderly (diagnosed after 40 years old). We isolated vesicular miRNA from the plasma of these patients and then assessed their miRNA levels using a high-throughput and high-resolution technique based on digital barcode hybridization.

2023-09-25 | GSE241785 | GEO

A Gene Expression-Based Risk Stratification Model for Newly Diagnosed Multiple Myeloma

Project description:We recently defined a gene expression-based signature of high-risk multiple myeloma; this predictive signature was developed with and independently validated for newly diagnosed patients treated with high dose therapy and stem cell rescue. Here we use Phase 3 clinical trial data to show that this signature also predicts short survival in relapsed disease treated with single agent bortezomib or high dose dexamethasone. In addition, a survival signature derived with relapsed myeloma samples identified newly diagnosed patients with short survival. Taken together these data suggest that a similar biology underlies poor outcome in both newly diagnosed and relapsed myeloma and provide strong evidence that the high-risk signature is a powerful tool to identify patients who are candidates for new therapeutic regimens. Keywords: Model validation

2011-08-20 | GSE8991 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data